79188650 - ANEMOCYTE

Information

• Trademark
• 79188650

• Source

• Serial Number

  79188650

• Registration Number

  5215720

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 10 - Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  September 11, 2015
  9 years ago

• Registration Date

  June 06, 2017
  7 years ago

• Transaction Date

  February 28, 2025
  2 months ago

• Status Date

  February 28, 2025
  2 months ago

• Published for Opposition Date

  March 21, 2017
  8 years ago

• Location Date

  February 28, 2025
  2 months ago

• Status Code

  706

• Current Location

  Historical data usage

  Employee Name

  SAUNDERS, ANDREA

• Attorney Docket Number

  7955-0065

  Attorney Name

  Brian A. Tollefson

• Owners

  • ARETA INTERNATIONAL S.r.l
  • ANEMOCYTE S.R.L.

Case File Statements

• GS0051: Pharmaceutical and veterinary preparations, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for use in human [ and veterinary ] medicine; chemical preparations for pharmaceutical or medical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets, syringes, infusion bags, vials and pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, nk cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, products for gene therapy, namely, genetically modified cells, viral vectors, nucleic acids; tissue engineered products, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace or restore a lost or impaired tissue or function; products for regenerative medicine, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace, restore or promote the repair, replacement or regeneration of a lost or impaired tissue or function; products for personalized medicine made of autologous cells or proteins or nucleid acids derived from individual genomic sequences; preparations made up of cells for medical or clinical use; preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes; preparations made up of tissues, namely, biological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy
• GS0101: [ Surgical apparatus and instruments for medical, dental and veterinary use; medical devices for the introduction of pharmaceutical preparations in the human body, in particular syringes and catheters; medical equipment, namely, centrifuges or other separation devices for the isolation of cell sub-populations from tissues and biopsies; surgical apparatus and instruments for medical and veterinary purpose; electrical medical instruments for use in electroporation of cells and tissues for gene transfer purposes, both in vivo and ex-vivo; electronic medical instruments for use in imaging for diagnostic purposes or for monitoring of vital signs of patients ]
• GS0421: Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; Providing medical and scientific research information and data on developments in the medical and veterinary fields; scientific and technological services, namely, scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; consultancy to ensure compliance with quality standards and the design and validation of manufacturing processes in the scientific field and medical technology fields

Case File Event Statements

• 7/8/2016 - 8 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 7/7/2016 - 8 years ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR

• 7/8/2016 - 8 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 7/11/2016 - 8 years ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 7/12/2016 - 8 years ago

  5 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 7/12/2016 - 8 years ago

  6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 7/13/2016 - 8 years ago

  7 - REFUSAL PROCESSED BY MPU Type: RFRR

• 7/13/2016 - 8 years ago

  8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 7/29/2016 - 8 years ago

  9 - REFUSAL PROCESSED BY IB Type: RFNT

• 10/11/2016 - 8 years ago

  10 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 10/11/2016 - 8 years ago

  11 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 11/16/2016 - 8 years ago

  12 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 12/7/2016 - 8 years ago

  13 - ASSIGNED TO LIE Type: ALIE

• 12/22/2016 - 8 years ago

  14 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 12/22/2016 - 8 years ago

  15 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 1/8/2017 - 8 years ago

  16 - FINAL REFUSAL WRITTEN Type: CNFR

• 1/8/2017 - 8 years ago

  17 - FINAL REFUSAL E-MAILED Type: GNFR

• 1/8/2017 - 8 years ago

  18 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN

• 2/1/2017 - 8 years ago

  19 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 2/1/2017 - 8 years ago

  20 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 2/1/2017 - 8 years ago

  21 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 2/1/2017 - 8 years ago

  22 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 2/1/2017 - 8 years ago

  23 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 2/1/2017 - 8 years ago

  24 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 2/1/2017 - 8 years ago

  25 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 2/1/2017 - 8 years ago

  26 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 2/1/2017 - 8 years ago

  27 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 2/14/2017 - 8 years ago

  28 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV

• 3/1/2017 - 8 years ago

  29 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 3/1/2017 - 8 years ago

  30 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R

• 3/1/2017 - 8 years ago

  31 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS

• 3/17/2017 - 8 years ago

  32 - NOTIFICATION PROCESSED BY IB Type: GPNX

• 3/21/2017 - 8 years ago

  33 - PUBLISHED FOR OPPOSITION Type: PUBO

• 3/21/2017 - 8 years ago

  34 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 6/6/2017 - 7 years ago

  35 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 9/6/2017 - 7 years ago

  36 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR

• 9/14/2017 - 7 years ago

  37 - FINAL DISPOSITION PROCESSED Type: FIMP

• 9/14/2017 - 7 years ago

  38 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS

• 10/28/2017 - 7 years ago

  39 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO

• 2/22/2018 - 7 years ago

  40 - CHANGE OF NAME/ADDRESS REC'D FROM IB Type: ADCH

• 4/9/2021 - 4 years ago

  41 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP

• 6/6/2022 - 2 years ago

  42 - COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Type: REM3

• 10/24/2022 - 2 years ago

  43 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR

• 10/24/2022 - 2 years ago

  44 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 10/24/2022 - 2 years ago

  45 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 10/24/2022 - 2 years ago

  46 - TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Type: EWAF

• 10/24/2022 - 2 years ago

  47 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR

• 10/24/2022 - 2 years ago

  48 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 10/24/2022 - 2 years ago

  49 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN

• 6/5/2023 - a year ago

  50 - TEAS SECTION 71 RECEIVED Type: ES71

• 2/12/2024 - a year ago

  51 - CASE ASSIGNED TO POST REGISTRATION PARALEGAL Type: APRE

• 2/24/2024 - a year ago

  52 - POST REGISTRATION ACTION MAILED - SEC.71 Type: PR71

• 8/21/2024 - 9 months ago

  53 - TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED Type: EROP

• 2/28/2025 - 2 months ago

  56 - REGISTERED-SEC.71 ACCEPTED Type: 71AG

• 2/28/2025 - 2 months ago

  57 - NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED Type: NA71

• 11/15/2024 - 6 months ago

  55 - INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE Type: INNA

• 10/25/2024 - 7 months ago

  54 - PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED Type: INPR